Heidelberg Pharma（HPHA）株式概要
ハイデルベルグ・ファーマAGはバイオ医薬品会社で、ドイツ、米国および国際的に、がん領域と抗体標的アマニチン結合体（ATAC）に注力している。 詳細
HPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Heidelberg Pharma AG 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €2.75 |
| 52週高値 | €5.36 |
| 52週安値 | €2.33 |
| ベータ | 0.74 |
| 1ヶ月の変化 | -0.36% |
| 3ヶ月変化 | -9.24% |
| 1年変化 | -17.66% |
| 3年間の変化 | -30.73% |
| 5年間の変化 | -58.08% |
| IPOからの変化 | -94.80% |
最新ニュース
ナラティブの更新 • May 11
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.ナラティブの更新 • Apr 22
HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).
新しいナラティブ • Apr 16
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?Recent updates
ナラティブの更新 • May 11
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.ナラティブの更新 • Apr 22
HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).新しいナラティブ • Apr 16
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Apr 08
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have maintained their price target for Heidelberg Pharma at €6.75, citing updated assumptions that combine a very large projected revenue growth rate with an unchanged profit margin and a lower future P/E multiple. What's in the News Heidelberg Pharma plans to present preclinical data for its Amanitin-based ADC candidate HDP-103 for metastatic castration-resistant prostate cancer at the AACR Annual Meeting 2026 in San Diego, with a poster session scheduled on 21 April from 2:00 pm to 5:00 pm PDT (company announcement).
新しいナラティブ • Apr 01
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Mar 24
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have kept their €6.75 price target for Heidelberg Pharma broadly unchanged, citing only marginal shifts in inputs such as the discount rate, long term profit margin assumptions and future P/E, which together leave their overall valuation view effectively steady. What's in the News Huadong Medicine has reached a development milestone under its 2022 license agreement with Heidelberg Pharma, triggering a milestone payment to Heidelberg Pharma, with financial details not disclosed (company announcement).ナラティブの更新 • Mar 08
HPHA: Steady Assumptions And Undervalued Outlook Will Support Future Upside
Analysts are keeping their price target for Heidelberg Pharma steady at €6.75. They cite only marginal tweaks to their discount rate and long term assumptions for revenue growth, profit margin and future P/E, rather than any shift in their core view on the stock.ナラティブの更新 • Feb 21
HPHA: New Leadership And High Growth Assumptions Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer of Heidelberg Pharma AG, effective immediately (Key Developments).ナラティブの更新 • Feb 07
HPHA: Leadership Transition And Stable Outlook Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75. They point to only small shifts in inputs such as the discount rate and the assumed future P/E multiple as reasons for maintaining their existing view.ナラティブの更新 • Jan 24
HPHA: Positive Trial Data And New Leadership Will Support Future Upside
Analysts have revised their price target for Heidelberg Pharma from €10.56 to €6.75, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E that change their assessment of the company’s risk profile and earnings potential. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer and appointed Dr Dongzhou Jeffery Liu as the new CEO with immediate effect.
新しいナラティブ • Apr 13
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.分析記事 • Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Heidelberg Pharma AG's ( ETR:HPHA ) price-to-sales (or "P/S") ratio of 15x might make it look like a strong sell right...分析記事 • Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Celebrations may be in order for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, with the analysts delivering a...分析記事 • Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Heidelberg Pharma AG ( ETR:HPHA ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
The analysts covering Heidelberg Pharma AG ( ETR:HPHA ) delivered a dose of negativity to shareholders today, by making...分析記事 • Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, Heidelberg Pharma...分析記事 • Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Heidelberg Pharma AG ( ETR:HPHA ) shareholders might be concerned after seeing the share price drop 14% in the last...分析記事 • Dec 14
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...株主還元
| HPHA | DE Biotechs | DE 市場 | |
|---|---|---|---|
| 7D | -1.8% | -1.0% | 0.6% |
| 1Y | -17.7% | -11.9% | 0.2% |
業界別リターン: HPHA過去 1 年間で-11.9 % の収益を上げたGerman Biotechs業界を下回りました。
リターン対市場: HPHAは、過去 1 年間で0.2 % のリターンを上げたGerman市場を下回りました。
価格変動
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
安定した株価: HPHA 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: HPHAの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1997 | 111 | Jeffery Liu | heidelberg-pharma.com |
ハイデルベルグ・ファーマ社はバイオ医薬品企業であり、ドイツ、米国および国際的に、がん領域および抗体標的アマニチン結合体（ATAC）に注力している。同社の主要製品候補には、再発または難治性の多発性骨髄腫の治療薬として第I/IIa相試験を実施中の抗BCMA抗体HDP-101がある。同社は、非ホジキンリンパ腫の治療薬として前臨床開発を完了した抗体および化合物AmanitinのHDP-102、転移性去勢抵抗性前立腺癌の治療薬として独自のATAC候補であるHDP-103、消化器腫瘍の治療薬であるHDP-104、大腸癌の治療薬であるHDP-201、および腫瘍の治療薬であるTAK-ATACを開発している。また、腎癌の診断用抗体TLX250-CDxを開発し、膀胱癌の治療薬として臨床第3相試験を実施中である。さらに、腎臓がん治療薬としてフェーズⅡ試験中の治療用抗体TLX250（girentuximab）、COVID-19治療薬としてフェーズⅡ試験中の経口セリンプロテアーゼ阻害剤RHB-107も開発している。また、HDP-101およびHDP-103のアジアにおける開発および商業化権について、華東医薬有限公司とライセンス契約および戦略的パートナーシップを結んでいる。同社は以前Wilex AGとして知られていたが、2017年10月にHeidelberg Pharma AGに社名を変更した。ハイデルベルク・ファーマAGは1997年に設立され、ドイツのラデンブルクに本社を置いている。
Heidelberg Pharma AG 基礎のまとめ
| HPHA 基礎統計学 | |
|---|---|
| 時価総額 | €128.66m |
| 収益（TTM） | -€40.62m |
| 売上高(TTM) | €2.65m |
48.5x
P/Sレシオ-3.2x
PER（株価収益率HPHA は割高か？
公正価値と評価分析を参照収益と収入
| HPHA 損益計算書（TTM） | |
|---|---|
| 収益 | €2.65m |
| 売上原価 | €602.44k |
| 売上総利益 | €2.05m |
| その他の費用 | €42.67m |
| 収益 | -€40.62m |
直近の収益報告
Feb 28, 2026
次回決算日
Jul 15, 2026
| 一株当たり利益（EPS） | -0.87 |
| グロス・マージン | 77.28% |
| 純利益率 | -1,531.69% |
| 有利子負債／自己資本比率 | 0% |
HPHA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 09:57 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/02/28 |
| 年間収益 | 2025/11/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Heidelberg Pharma AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |